Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2016-05-24
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of and best dose of tivantinib when given
together with bevacizumab in treating patients with solid tumors that have spread to other
areas of the body or cannot be removed by surgery. Tivantinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
bevacizumab, may block tumor growth in different ways by targeting certain cells. Bevacizumab
may also stop the growth of cancer by blocking blood flow to the tumor. Giving tivantinib
together with bevacizumab may work better in treating tumor cells.